Novel pathways of heart failure with preserved ejection fraction by Li, Shanpeng
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Novel pathways of heart failure
with preserved ejection fraction
https://hdl.handle.net/2144/16263
Boston University
	   	   	  
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
NOVEL PATHWAYS OF HEART FAILURE WITH  
PRESERVED EJECTION FRACTION 
 
 
 
 
by 
 
 
 
 
SHANPENG LI 
 
B.S., University of California Los Angeles, 2011 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2015  
	   	   	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 by 
 Shanpeng Li  
 All rights reserved  
	   	   	  
Approved by 
 
 
 
 
First Reader   
 Dr. Flora Sam, M.D., FACC, FAHA  
 Associate Professor of Medicine 
 
 
 
 
 
 
Second Reader  
 Maria Valero Munoz, Ph.D.  
 Postdoctoral Researcher   
  
 
 
 
 
 
	  	   iv 
ACKNOWLEDGMENTS 
 My sincerest gratitude belongs to all those who have been instrumental in 
the completion of this thesis: 
 
To Dr. Flora Sam, M.D., who welcomed me into her laboratory and provided me 
with this extraordinary opportunity. Thank you so much for your constant 
guidance and motivation that supported me throughout this journey. You have 
truly been a great mentor and role model, and I look forward to continue working 
with you in the future.  
 
To Maria Valero Munoz, Ph.D., for being the greatest mentor I have ever met. 
Thank you for always being patient with me and teaching me invaluable lessons 
and techniques throughout this year. This year has been a year of substantial 
growth due to your help and I will always be able to apply the skills I learned from 
you in my future.  
 
To Richard Wilson, B.A., thank you for being a wonderful labmate who is always 
available for help and advice. Your constant support and patience always made 
me feel comfortable and confident in the laboratory.  
 
To Vassili Glazyrine, B.A., thank you for a great classmate and lab partner 
throughout even the toughest moments of this graduate program. We have made 
	  	   v 
it this far and I sincerely wish we have success in both of our careers in the 
future.  
 
To Dr. Stephanie Oberhaus, Ph.D., thank you for being a constant source of 
advice and encouragement throughout this graduate program. I could not have 
performed as well without your help and thoughtfulness. Your dinner gatherings 
throughout the program have been extremely helpful for advice from previous 
MAMS graduates and showing us the light at the end of the tunnel. Lastly, thank 
you for introducing me to Dr. Sam as this year has been a wonderful experience.  
  
	  	   vi 
NOVEL PATHWAYS OF HEART FAILURE WITH 
 
PRESERVED EJECTION FRACTION 
SHANPENG LI 
Abstract 
 
Introduction: 
Diastolic heart failure (HF) i.e., HF with preserved ejection fraction (HFpEF) 
accounts for ~50% of all clinical HF presentations; but unlike systolic HF i.e., HF 
with reduced ejection fraction (HFrEF), there are no evidenced based therapies. 
Obesity is commonly associated with HFpEF. However, there exist a sub-group 
of obese patients that exhibit a higher survival rate to HFpEF as compared to 
average patients. Hypertension is the most important risk factor for HFpEF, with 
a prevalence of 60-89% reported by large controlled trials, epidemiological 
studies and HF registries. HFpEF morbidity and mortality rates are staggering: 
50-60% 5 year mortality rate, 50% 6 month rehospitalization rate and severe 
clinical disability.  However, there remains an incomplete mechanistic 
understanding about HFpEF.  
 
Objectives: 
We wanted to explore new pathways related to HFpEF in order to better 
understand the mechamisms behind its pathophysiology. To do so, we first 
wanted to explore the potential crosstalk between the heart and adipose tissue 
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during HFpEF by analyzing the adipose tissue in our HFpEF model. Secondly, 
we sought to test the hypothesis that chronic ETA/ETB inhibition with macitentan 
(mac) modulates pathologic cardiac remodeling in hypertension-induced HFpEF.  
 
Methods: 
Mice (20-25 g) were anesthetized, underwent uninephrectomy and received 
either a continuous infusion of saline (sham) or d-aldosterone (0.3 ug/hour for 4-
weeks via osmotic minipumps). All mice were maintained on standard rodent 
chow and 1.0% sodium chloride drinking water for 4 weeks and then harvested.  
Second group of mice underwent the same surgical procedure and infusion. 
They were maintained on standard chow for 2 weeks and then each group was 
randomized to chow containing macitentan (30 mg/kg/day, HFpEFmac) or 
standard rodent chow. After 2 additional weeks, the 4 groups of mice (n=4-
8/group) were harvested. 
Blood pressure (BP) was obtained weekly. Prior to sacrifice, body weight and 
echocardiography parameters (total wall thickness (TWT) and relative wall 
thickness (RWT)) were determined. We also obtained diastolic dysfunction 
parameters including deceleration time (DT), isovolumetric relaxation time 
(IVRT), and E/A ratio. Furthermore, we measured organ weight after harvesting 
the mice and obtained histological images for the adipose tissues collected. 
Glucose tolerance test and acute cold tolerance test were performed on HFpEF 
mice to determine their metabolic state.  
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Results: 
HFpEF mice developed hypertension, LV hypertrophy, and diastolic dysfunction. 
Epididymal and inguinal adipose tissue showed significantly reduced weight and 
adipocyte size. HFpEF mice displayed regular glucose metabolism but were not 
able to endure a cold tolerance test as their body temperature dropped too low.  
After 4 weeks, there was no difference in body weight between sham, HFpEF, 
shammac and HFpEFmac. As expected HFpEF increased systolic BP (117±14 vs 
133±16mmHg; P=NS); macitentan did not lower systolic BP after 2 weeks in 
either shammac or HFpEFmac. Similarly there was no difference in systolic BP 
between HFpEF and HFpEFmac. Both kidney and spleen weights were increased 
in HFpEF but not altered by macitentan therapy. There was no change in lung 
congestion as measured by wet-dry lung ratio.  
HFpEF increased TWT (0.998±0.04 vs. 0.79±0.11 mm; P<0.01 vs. sham) and 
RWT (0.686± 0.10 vs. 0.476±0.05 mm; P<0.001 vs. sham) but were modulated 
by macitentan (HFpEF vs. HFpEFmac; P<0.05 and P<0.001, respectively). There 
was no difference in chamber size between HFpEF and HFpEFmac. Similarly, 
IVRT, DT, left ventricular ejection fraction were no different between HFpEF and 
and HFpEFmac. Furthermore E/A ratio was increased in HFpEF but was not 
affected by macitentan  
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Conclusions. 
Adipose tissue collected from our HFpEF mice displayed a very different 
phenotype. This demonstrates that inter-tissue communication is definitely 
occurring between the adipose tissue and the heart. Further research is required 
to explore what that communication encompasses and how they can be used to 
improve HFpEF. 
 
Macitentan did not lower systolic BP in sham or mice with HFpEF after the 
development of hypertension. Diastolic dysfunction, as measured by an 
increased E/A ratio, was not affected by macitentan. Macitentan significantly 
modulated TWT and RWT after 2 weeks of therapy. It is thus plausible that 
macitentan may improve HFpEF by improving adverse cardiac remodeling. 
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INTRODUCTION 
 
Diastolic heart failure (HF) i.e., HF with preserved ejection fraction 
(HFpEF) accounts for ~50% of all clinical HF presentations; but unlike systolic HF 
i.e., HF with reduced ejection fraction (HFrEF), there are no evidenced based 
therapies. HFpEF morbidity and mortality rates are staggering: 50-60% 5 year 
mortality rate, 50% 6 month rehospitalization rate and severe clinical disability. 
Although hypertension and obesity are both commonly associated with HFpEF, 
there remains an incomplete mechanistic and diagnostic understanding about 
HFpEF. (Essick et al. 2013) Several criteria have been proposed to define the 
syndrome of HFpEF through the American Heart Association Guidelines. These 
include a) clinical signs or symptoms of HF; b) evidence of preserved or normal 
LVEF; and c) evidence of abnormal LV diastolic dysfunction that can be 
determined by Doppler echocardiography or cardiac catheterization. In the 
general population, patients with HFpEF are usually older women with a history 
of hypertension. Obesity, coronary artery disease, diabetes mellitus, atrial 
fibrillation (AF), and hyperlipidemia are also highly prevalent co-morbidities found 
in HFpEF patients in population-based studies and registries. Despite these 
associated cardiovascular risk factors, hypertension remains the most important 
cause of HFpEF, with a prevalence of 60% to 89%. (Yancy et al. 2013) Some of 
the risk factors associated with HFpEF are shown in Figure 1. We will be 
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focusing on exploring obesity and hypertension induced HFpEF and the 
mechanisms behind them.  
 
 
Figure 1. Risk Factors Associated with HFrEF and HFpEF 
Major risk factors associated with HFrEF and HFpEF are shown in this figure with 
factors of greater importance showing bigger arrows. In terms of HFpEF, obesity, 
aging, gender/sex, and hypertension are very important risk factors that many 
patients demonstrate. Figure taken from Borlaug 2013. 
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Obesity and Heart Failure 
 Obesity is defined as abnormal or excessive fat accumulation that 
presents a risk to health. (Carbone 2013) Currently, obesity is defined based on 
the Body Mass Index (BMI), which relates height to weight. A BMI greater than or 
equal to 30 kg/m2 defines obesity. According to this criterion, more than 35% of 
the USA population is considered obese. With HF being a disease associated 
with many co-morbidities, obesity is commonly seen in HFpEF. During obesity, 
there is adipose tissue dysfunction, so called “adiposopathy”, which is a pro-
inflammatory state and adversely affects metabolism and cardiovascular function 
via autocrine, paracrine or endocrine mechanisms. The effects of adipokines 
secreted by adipose tissue on the cardiovascular system have been widely 
described. Accelerated CAD is associated with an adipokine imbalance with 
increased expression and secretion of pro-inflammatory adipokines such as 
TNFα, leptin and MCP-1, whilst anti-inflammatory adipokines such as adiponectin 
(APN) are decreased (Tilg and Moschen 2006; Van de Voorde et al. 2013; Ouchi 
et al. 2011; Gualillo, González-Juanatey, and Lago 2007; Romacho et al. 2014). 
Many other mechanisms have been proposed to explain how obesity leads to 
heart failure, some of them are demonstrated in Figure 1 showing alterations in 
blood volume leading up hemodynamic alterations which eventually induce 
cardiac structural abnormalities.  
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Figure 2. Pathophysiology of Obesity Cardiomyopathy 
This figure shows the central hemodynamic, cardiac structural abnormalities and 
alterations in ventricular function that may occur in severely obese patients and 
predispose them to heart failure. In severely obese patients presenting with 
systemic hypertension, concentric LV hypertrophy is more frequently observed 
which leads to diastolic heart failure. Figure taken from Lavie et al. 2013. 
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The Obesity Paradox 
It has been widely interpreted that obesity exerts major deleterious effects 
on our body and it is the cause of numerous illnesses such as metabolic 
syndrome and cardiovascular diseases. However, there exist evidence that lead 
to the “obesity paradox” which is a concept stating certain patients with obesity 
have an improved survival rate to particular illnesses than a non-obese patient 
measured by BMI and other indices. Evidence has shown that obesity has also 
been linked to improved HF survival in observational studies. In a randomized 
controlled trial of 7599 patients with symptomatic HF with either reduced or 
preserved systolic function showed that patients in lower BMI categories had a 
graded increase in the risk of death; the group with the highest BMI (>35 kg/m2) 
had similar risk to those with a BMI of 30.0–34.9 kg/m2) (Clark, Fonarow, and 
Horwich 2014) This evidence points to the existence of two possible obese 
phenotypes, the metabolically healthy (MHO) and metabolically unhealthy 
(MUHO). Some key characteristics of the MHO phenotype include lack of insulin 
resistance, no hypertension, as well as a favorable lipid, inflammatory, and 
immune profile. (Primeau et al. 2011)  
This points to an interesting relationship between obesity and HF.  Before 
developing HF, data has shown that for every incremental increase in BMI, there 
is a higher chance of developing HF in the individual. However, on the contrary, 
despite the adverse effects of obesity on systolic and diastolic parameters, it has 
been demonstrated that the best prognosis in HF occurred in overweight 
	   6	  
patients, followed closely by obese patients, and the worst prognosis occurred in 
underweight HF patients, followed closely by patients with "normal" BMI. (Lavie 
et al. 2013) The obesity paradox is a contradiction that many have tried to 
explain the mechanisms behind. Some proposed mechanisms are: more 
metabolic reserve in obese patients, various protective cytokines, soluble tumor 
necrosis factors being protective by neutralizing adverse biological effects, and 
attenuated response of renin-angiotensin-aldosterone system (RAAS), more are 
listed in Table 1(Kalantar-Zadeh et al. 2004; Mohamed-Ali et al. 1999; Anker et 
al. 2003) When it comes to HFpEF, previous research has shown that cytokines 
from the adipose tissue plays a very important role in modulating cardiac 
remodeling and diastolic dysfunction. One such cytokine is adiponectin, which is 
an adipocyte-derived cytokine that is capable of modulating insulin resistance, 
coronary artery disease, and hypertension. (Ohashi et al. 2006; Ouchi et al. 
2003) In HFpEF, adiponectin and aldosterone levels appear to be in opposition 
with aldosterone level increasing and adiponectin level decreasing (Ouchi et al. 
2003; Goodfriend and Calhoun 2004; Calhoun 2006). Sam et al. further 
demonstrated the importance of adiponectin in HFpEF by comparing diastolic 
parameters in adiponectin knockout mice (APNKO), which showed exacerbated 
diastolic dysfunction parameters. This shows the adipose tissue may play a 
critical role in HFpEF by inter-tissue communication which prompted us to further 
explore the role of adipose tissue in HFpEF. With a better understanding of the 
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mechanisms behind the inter-tissue communication and the involved signaling 
mechanisms, novel treatment for HFpEF can be identified.  
 
Table 1. Potential Reasons for the Obesity Paradox In Heart Failure 
This table lists the possible explanations of Obesity Paradox in Heart Failure. We 
wanted to focus on the protective roles of cytokines and the mechanisms behind 
their communication.  
Figure taken from Lavie et al. 2013. 
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Hypertension and HFpEF 
 HFpEF is a complex disease often presenting with multisystem 
involvement characteristics including skeletal muscle and vascular dysfunction, 
pulmonary hypertension, renal failure, anemia, and atrial fibrillation. (Maeder and 
Kaye 2009) The prevalence of HFpEF compared to HFrEF is rising at an 
alarming rate of 1% per year, which is rapidly turning HFpEF into the most 
prevalent HF phenotype with little to no improvement in outcome. (Owan et al. 
2006) Since obesity and hypertension occur often together, we studied 
hypertension as a cause of HFpEF. HFpEF is associated with relative increases 
in aldosterone levels so the Sam lab developed a murine model of hypertension 
induced HFpEF through chronic aldosterone infusion. Aldosterone contributes 
greatly to the development of hypertension. This role has been supported by 
numerous cross-sectional studies relating plasma aldosterone level to 
ambulatory blood pressure (BP) measurements. (Calhoun 2006) It is further 
supported by the antihypertensive efficacy of aldosterone antagonists in treating 
hypertension. 
Both HFpEF and HFrEF are associated with systemic and cardiac 
activation of the renin-angiotensin-aldosterone system (RAAS). Aldosterone 
levels have been shown to be significantly elevated in HF patients. Aldosterone 
is involved in the inflammatory response and cause myocyte hypertrophy, death, 
apoptosis, and altered protein expression of enzymes in the oxidation pathway of 
long chain fatty acid and reactive oxygen species in both in vivo and in vitro 
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models.  Aldosterone is also produced in the heart and is responsible for 
mediating cardiac remodeling and fibrosis. (Silvestre et al. 1998). These 
evidences led to testing of anti-aldosterone treatments such as spironolactone for 
HFpEF. During the Treatment of Preserved Cardiac Function Heart Failure with 
an Aldosterone Antagonist (TOPCAT) trial, spironolactone, a mineralocorticoid 
receptor blocker, was used to treat patients with HFpEF. Despite being able to 
reduce diastolic dysfunction parameters in these patients, spironolactone was not 
able to significantly reduce the composite primary end point of death from 
cardiovascular causes, aborted cardiac arrest, or hospitalization for heart failure. 
(Pitt et al. 2014) This led us to address other possible mechanisms for the 
treatment of HFpEF. 
 
Overview of Endothelin-1 and Endothelin Receptor Antagonists (ERA) 
Preclinical and clinical evidence indicate that aldosterone and endothelin-1 
(ET-1) may interact and hyperaldosteronism is often associated with elevated 
ET-1 levels.  ET-1 is a 21-amino acid peptide that is produced mainly endothelial 
cells as well as several other tissues including lung, heart, kidney, liver, brain, 
and some circulating cells. (Nunez et al. 1990; Firth and Ratcliffe 1992) ET-1 acts 
in a paracrine and autocrine manner to regulate vasoconstriction, cell 
proliferation, cell migration, and fibrosis (Temple et al. 2014). Endothelial cells 
tend to release ET-1 abluminally resulting in only a minor portion (~20%) of the 
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ET-1 being released into the blood. This shows that plasma level of ET-1 cannot 
be used to estimate ET-1 activity.  
ET-1 acts on its target tissues through two receptors, endothelin receptor 
A and B (ETA, ETB). The ETA and ETB receptors are members of the 
heptahelical G-protein-coupled receptor superfamily, range from 45 to 50 kDa in 
size (Levin 1995). In systemic and pulmonary vessels, ETA receptors are 
primarily located on the vascular smooth muscle cells (VSMCs) and ETB 
receptors are located on both endothelial cells and VSMCs. Both receptors act in 
similar fashion by mediating vasoconstriction and proliferation with the exception 
of ETB also activating the release of vasodilating factors such as prostacyclin 
and nitric oxide. ETB receptor is also responsible for the clearance of ET-1 
through the lungs (Clozel et al. 1992; Docherty and MacLean 1998; MacLean, 
McCulloch, and Baird 1994). ETA and ETB receptors are found in numerous 
tissues such as lung, heart, kidney, intestine, eye, and brain, but the density is 
especially high in lung and heart demonstrating where ET-1 has the most effect 
(Simonson and Dunn 1990). Figure 2 shows the main actions mediated by ET-1.  
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Figure 3. Actions of ET-1 on ETA  and ETB  Receptors 
This figure demonstrates the difference effects ET-1 has depending on the 
receptor it is acting on. Similar effects of ETA and ETB receptors include 
vasoconstriction, angiogenesis, and mitogenesis. ET-B receptor is responsible 
for vasodilation and ET clearance. Figure taken from Motte, McEntee, and Naeije 
2006.  
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All these biological effects show the major involvement of ET-1 in 
cardiovascular conditions. This led researchers to explore the therapeutic 
potential of endothelin receptor antagonists (ERA) in conditions such as 
pulmonary arterial hypertension (PAH), congestive heart failure (CHF), vascular 
remodeling, and subarachnoid hemorrhage, with the majority being focused on 
PAH (Motte, McEntee, and Naeije 2006) (Figure 3). There are currently three 
types of ERA available: selective antagonists to the ETA receptor, selective 
antagonists to the ETB receptor, and non-selective antagonists that block both 
receptors. Numerous experiments have been conducted using all three types of 
ERA mostly focused on PAH. Evidence suggests using selective ERA is effective 
against cardiovascular conditions such that it’s able to partially prevent vascular 
constriction and remodeling. However, actions of ET-1 through the non-
antagonized receptor are still present.  Data suggests blocking both receptors 
being more effective than using selective ERA (Sato et al. 1995). 
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Figure 4. Endothelin Associated Diseases 
This figure shows diseases with increased levels of ET-1. Notably, it includes HF 
and arterial hypertension. The variable biological activity of ET-1 is why ERAs 
are being researched as treatment for most of the diseases shown.  
  
 
There are numerous dual ETA/ETB inhibitors in the market today with 
bosentan being the first approved by the FDA. Use of the dual ETA/ETB receptor 
antagonist bosentan has been effective for treating PAH in large clinical trials 
(Rubin et al. 2002). It has been shown also to be able to lower aldosterone levels 
in patients with congestive HF (Sütsch et al. 2000). A more recent dual ERA 
approved by the FDA, macitentan, has demonstrated higher efficacy than 
bosentan in vivo. Macitentan showed a significant 45% reduction in the combined 
endpoint of morbidity and mortality in the long term SERAPHIN trial for patients 
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suffering from PAH (Pulido et al. 2013). Furthermore, it is a dual ETA/ETB 
antagonist with increased tissue distribution and slow receptor disassociation 
which allows sustained receptor occupancy time (Iglarz et al. 2014). Lastly, 
macitentan also has an active metabolite ACT-132577 that has a longer half-life, 
which also contributes to the pharmacological activity of macitentan (Iglarz et al. 
2008).  
For all these reasons, we aimed to test the hypothesis that chronic 
ETA/ETB inhibitor (macitentan) modulates LV hypertrophy and pathologic 
myocardial remodeling in our murine model of hypertension-induced HFpEF.  
Aims 
1. Evaluate the effect of HFpEF on adipose tissue and potential crosstalk 
between the heart and adipose tissue. 
2. Evaluate the effect of ET-1 on HFpEF development using dual ERA 
macitentan. 
Hypothesis 
1. During HFpEF there is crosstalk between the heart and adipose tissue 
that can lead to changes in adipose tissue through signals released from 
the heart. 
2. Because it is well know that ET-1 inhibitors are able to attenuate 
aldosterone levels and PAH in patients, we assumed macitentan 
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treatment is able to improve HFpEF. 
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MATERIAL AND METHODS 
 
Obesity 
 
Mice. 
Eight-weeks C57BL/6J old male were obtained from the Jackson Laboratory and 
were maintained on a 12:12-h light-dark cycle in a temperature-controlled (19–
21°C) room. Mice were maintained on standard rodent chow and 1.0% sodium 
chloride drinking water ad libitum for 4 weeks. The Institutional Animal Care and 
Use Committee at Boston University School of Medicine approved all study 
procedures related to the handling and surgery of the mice.  
 
Hypertension-induced HFpEF model. 
Mice were anesthetized with 80–100 mg/kg ketamine and 5–10 mg/kg xylazine 
intraperitoneally. All mice (20–25 g) underwent left uninephrectomy. The left 
renal artery was securely ligated with suture before carefully removing the left 
kidney. After surgery, the mice received either a continuous infusion of saline 
(Sham) or d-aldosterone (0.30 µg/h, Sigma-Aldrich) (HFpEF) for 4 weeks via 
osmotic minipumps (Alzet, Durect).(Tanaka et al. 2014a; Tanaka et al. 2013) 
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Blood pressure measurement. 
Heart rate and blood pressure were measured weekly using a noninvasive tail-
cuff blood pressure analyzer, BP-2000 Blood Pressure Analysis System (Visitech 
Systems, Inc.). Mice were allowed to acclimate to the blood pressure analyzer by 
performing a preliminary run one day before week 0 measurement was 
performed. 5 preliminary measurements were always performed before actual 
measurements begin to allow adequate time for mice to relax.  
 
Echocardiography. 
Transthoracic echocardiography was performed at the end of 4 weeks using the 
Vevo 770 High-Resolution In Vivo Micro-Imaging System and a Real-Time Micro 
Visualization 707B Scanhead (VisualSonic Inc). To assess diastolic function, 
mice were anesthetized with isoflurane (3% for induction followed by 0.5 to 1.5% 
for maintenance) and maintained at a heart rate (HR) of ~350 beats per minute 
(bpm) since diastolic function is sensitive to HR and loading conditions. (Tanaka 
et al. 2014b) Long axis view of the heart was obtained through the left atrium 
(LA) and left ventricle (LV) and pulse wave measurements were recorded to 
measure diastolic function parameters. Measurements included Deceleration 
Time (DT), Peak E, Peak A, E/A Ratio, and Isovolumetric relaxation time (IVRT). 
Heart rate was then adjusted to 400+ bpm to measure systolic functions as lower 
HR impairs systolic parameters. Short axis view of LV was obtained and 
Interventricular septum wall thickness (IVST), LV posterior wall thickness 
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(LVPWT), LV end-diastolic diameter (LVEDD), LV end-systolic diameter 
(LVESD), and LV ejection fraction (LVEF) were measured. Total wall thickness 
(TWT) was derived from an average of the IVST and LVPWT. LV mass was 
calculated using the formula LV mass= 1.05[(LV EDD + IVST + PWT)3 - (LV 
EDD)3]. (Tanaka et al. 2014b) 
 
Body temperature and acute cold tolerance test. 
The last week of the experiment, animals were subjected to a cold tolerance test 
(CTT), and body temperature was measured every hour for 4 hours. During cold 
exposure, mice were kept in individual cages without access to food in a cold 
room (4-6ºC). Body weight was measured before and after performing the test. 
Mice were implanted with programmable subcutaneous microchip transponders 
(IPTT-300 Extended Accuracy Calibration; Bio Medic Data Systems) as 
instructed by the manufacturer. Temperature measurements from the microchip 
transponders were obtained using a compatible reader held at a distance of 5 to 
6 cm from the implantation area.  
 
Glucose levels and glucose tolerance test. 
Total glucose levels of each mouse were evaluated prior to sacrifice using an 
Accu-Chek glucometer (Roche Diagnostics Corp). For the glucose tolerance test 
(GTT), mice were injected intraperitoneally with 1g glucose/Kg body weight after 
16 hours of fasting. Blood glucose levels were measured immediately before and 
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15, 30, 60, 90, and 120 minutes after glucose injection. Areas under the curve 
(AUC) values were calculated using the GraphPad Prism software (GraphPad 
Software Inc.). 
 
Assessment of body composition. 
Body composition, including fat mass and lean tissue mass, was measured by 
non-invasive quantitative magnetic resonance imaging (EchoMRI-700, Echo 
Medical System). 
 
Histology 
Samples were fixed in 4 % paraformaldehyde immediately after collection during 
sacrifice. Samples were then dehydrated with consecutive 30 minutes washes of 
70%, 90%, 96% and 100% ethanol solutions followed by xylene wash and 
embedded in paraffin. 4µm-thick histological sections were stained with 
hematoxylin and eosin (H/E, Sigma-Aldrich) to examine tissue morphology. 
Adipocyte size was evaluated by computer-assisted morphometric analysis using 
Adiposoft (Galarraga et al. 2012). 
 
Statistical Analysis. 
Data are shown as mean ± SEM unless otherwise stated. Statistical significance 
of differences between two groups was assessed by paired Student’s t-tests. 
Results of GTT experiment were evaluated by two-way repeated measures 
	   20	  
ANOVA. Pearson correlation coefficients were used to examine the association 
among different variables. All statistical tests were performed using GraphPad 
Prism software (GraphPad Software Inc.). 
 
Macitentan  
 
HFpEF Model  
Eight-weeks C57BL/6J old male were obtained from the Jackson Laboratory and 
were maintained on a 12:12-h light-dark cycle in a temperature-controlled (19–
21°C) room. All mice underwent same uninephrectomy surgery as previously 
described. After surgery, the mice received either a continuous infusion of saline 
(Sham) or d-aldosterone (0.30 µg/h, Sigma-Aldrich) (HFpEF) for 4 weeks via 
osmotic minipumps (Alzet, Durect). All mice were maintained on standard rodent 
chow and 1.0% sodium chloride drinking water for the first 2 weeks and then 
each group was randomized to chow containing macitentan (30 mg/kg/day, 
HFpEFmac, shammac) or standard rodent chow. After 2 additional weeks, the 4 
groups of mice (n=4-8/group) were sacrificed. The Institutional Animal Care and 
Use Committee at Boston University School of Medicine approved all study 
procedures related to the handling and surgery of the mice. 
 
Echocardiography 
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Transthoracic echocardiography was performed at the end of each week using 
the Vevo 770 High-Resolution In Vivo Micro-Imaging System and a Real-Time 
Micro Visualization 707B Scanhead (VisualSonic Inc). Diastolic and systolic 
parameters were obtained following methods described previously.  
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RESULTS 
Obesity 
 
General characteristics 
 Characteristics of Sham vs HFpEF after saline or aldosterone infusion are 
summarized in Table 2. Body weights were comparable between sham and 
HFpEF mice with no significant differences. Relative weight for heart and spleen, 
were significantly increased in HFpEF mice. (Table 2) Relative weights of 
gastrocnemius muscle were significantly decreased in HFpEF mice. Relative 
weight for liver was comparable between sham and HFpEF. There was no 
difference in between percent body fat or percent body lean mass between sham 
and HFpEF mice. (Figure 6) 
 
Adipose tissue characteristics 
 After 4 weeks, the epidydimal and inguinal adipose tissue from our 
experimental HFpEF mice showed significant reduction in tissue weight and 
adipocyte size in both fat depots when compared to Sham (10.67±0.95 vs. 
7.59±0.57 mg/g of body weight, 8.38±0.84 vs. 6.34±0.47 mg/g of body weight 
respectively; p<0.01). On the contrary, there was a significant increase in brown 
adipose tissue weight in HFpEF mice compared to Sham (4.50±0.34 vs. 
5.96±0.42 mg/g of body weight; p<0.05). 
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Hemodynamic parameters 
 Heart rates were comparable between sham and HFpEF mice after 4 
weeks. (Table 2, Figure 12) Systolic blood pressure was measured weekly and 
was significantly increased by 4 weeks of aldosterone infusion in HFpEF mice 
compared with Sham mice. (131±3 vs. 146±3 mmHg;p<0.01) Similar to systolic 
BP, diastolic BP was also measured weekly and showed a significant increase in 
HFpEF mice compared to sham mice. (89±6 vs.114±4 mmHg; pP<0.01)  
 
LV structure and systolic function 
 Echocardiographic parameters for LV structure and systolic function are 
summarized in Table 3; Figure 10. Chronic aldosterone infusion significantly 
increased total wall thickness, LV mass, and interventricular septum wall 
thickness (IVS) in HFpEF mice, which was consistent with the relative heart 
weight. (2.15±0.06 mm, 126.62±4.23 mg, and 2.15±0.06 mm) There was no 
difference in LV end diastolic diameter and LV ejection fraction (LVEF) between 
sham and HFpEF mice.  
 
Diastolic function 
 Echocardiographic parameters (mitral Doppler) for LV diastolic function 
are summarized in Table 3; Figure 9. Chronic aldosterone infusion significantly 
shortened deceleration time (DT) in HFpEF mice, which indicates abnormal LV 
relaxation. (22.67±1.65 vs. 14.57±0.90 ms; P<0.0001) Isovolumetric relaxation 
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time was significantly lengthened in HFpEF mice, which again supports abnormal 
relaxation (20.36±2.06 vs. 26.73±1.21 ms; P<0.05). There was no difference in 
E/A ratio between Sham and HFpEF mice.  
 
Tolerance tests 
 Basal body temperature before performing acute cold tolerance test 
between Sham and HFpEF were comparable. Time course progression of body 
temperature shows increased rate of descend for HFpEF mice compared to 
Sham mice (Figure 11). Change in body weight measured after cold tolerance 
test shows significantly higher loss of body weight in HFpEF mice compared to 
sham mice (Figure 11). 
 Glucose tolerance test time course progression is shown in Figure 13. 
There was no difference in glucose metabolism capability between Sham and 
HFpEF mice.  
 
Macitentan Results 
After 4 weeks, there was no difference in body weight between sham, 
HFpEF, shammac and HFpEFmac groups. (Table 5) Both kidney and spleen 
weights were increased with chronic aldosterone infusion but not altered by 
macitentan therapy. Similarly there was no change in lung congestion as 
measured by wet-dry lung ratio (Table 5). As expected, HFpEF increased systolic 
BP (117±14 vs 133±16mmHg; P=NS); Macitentan (30 mg/kg/day) had no effect 
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on systolic BP after 4 weeks in either the shammac or HFpEFmac group. (Table 5) 
Similarly there was no difference in systolic BP between HFpEF and HFpEFmac. 
(Table 5). 
HFpEF increased TWT (0.998±0.04 vs. 0.79±0.11 mm; P<0.01 vs. sham) 
and RWT (0.686± 0.10 vs. 0.476±0.05 mm; P<0.001 vs. sham) (Table 4). The 
increase in TWT and RWT was modulated by macitentan (HFpEF vs.HFpEFmac; 
P<0.05 and P<0.001, respectively). There was no difference in chamber size 
between HFpEF and HFpEFmac. Similarly, IVRT, DT, left ventricular ejection 
fraction were no different between HFpEF and and HFpEFmac. (Table 4) However 
chronic aldosterone infusion increased the E/A ratio in HFpEF and HFpEFmac and 
was not modulated by macitentan. (Table 4)  
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Figure 5. General Characteristics of Epididymal and Inguinal Adipose 
Tissue. Section A shows the adipocyte size, histological images, and raw image 
of epididymal adipose tissue collected from sham and HFpEF Mice. Section B 
shows the adipocyte size, histological images, and raw tissue images of inguinal 
adipose tissue collected from sham and HFpEF mice.  
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Figure 6. General Characteristics of Brown Adipose Tissue and Total Body 
Composition. Section A shows the percent fat and percent lean body mass 
between sham and HFpEF mice with no significant differences between them. 
Section B shows histological images and raw tissue images of collected 
interscapular brown adipose tissue collected from sham and HFpEF mice.  
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Table 2. General characteristics of Sham and HFpEF mice after 4 weeks of 
Saline/Aldosterone infusion. All data were collected right before harvesting or 
after harvesting the necessary organs for measurements. Systolic BP, Diastolic 
BP, and HR were measured before harvesting.  
 Sham HFpEF 
Body weight (g) 26.6±1.0 26.3±0.4 
Heart weight / Body Weight (mg/g) 3.45±0.07 4.01±0.09*** 
Spleen weight / Body weight (mg/g) 3.29±0.09 3.77±0.08*** 
eWAT weight / Body weight (mg/g) 10.67±0.95 7.59±0.57** 
iWAT weight / Body weight (mg/g) 8.38±0.84 6.34±0.47* 
BAT weight / Body weight (mg/g) 4.50±0.34 5.96±0.42* 
Gastrocnemius weight / Body weight (mg/g) 5.66±0.16 4.90±0.22* 
Liver weight / Body weight (mg/g) 44.81±1.68 47.45±1.40 
Feed glucose levels (mg/dL) 203.0±11.2 211.0±13.7 
Systolic blood pressure (mm Hg) 131±3 146±3** 
Diastolic blood pressure (mm Hg) 89±6 114±4** 
Heart rate (beats/min) 666±29 623±16 
Data are expressed as mean ± SEM. Abbreviations: BAT, brown adipose tissue; 
eWAT, epididymal white adipose tissue; HFpEF, heart failure preserved ejection 
fraction; iWAT, inguinal white adipose tissue. *p<0.05 vs. Sham; **p<0.01 vs. 
Sham; ***p<0.001 vs. Sham 
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Table 3. Echocardiographic Parameters of Sham and HFpEF mice after 4 
weeks of Saline/Aldosterone infusion. All measurements were done 2-3 days 
prior to harvesting the experimental mice.  
 Sham HFpEF 
LV Structure   
LV mass (mg) 93.98±3.49 126.62±4.23*** 
Total wall thickness (mm) 1.69±0.06 2.15±0.06*** 
Interventricular septum wall thickness (mm) 0.91±0.02 1.30±0.05*** 
LV end- diastolic diameter (mm) 3.34±0.13 3.17±0.12 
Systolic Function   
LV ejection fraction (%) 82.18±3.05 87.81±2.05 
LV fractional shortening 50.67±3.24 57.77±2.69 
Diastolic Function   
E/A 1.26±0.09 1.11±0.02 
Deceleration time (ms) 22.67±1.65 14.57±0.90*** 
Isovolumetric relaxation time (ms) 20.36±2.06 26.73±1.21* 
Data are expressed as mean ± SEM. Abbreviations: IVS, intra-ventricular 
septum; LV, left ventricle. *p<0.05 vs. Sham; **p<0.01 vs. Sham; ***p<0.001 vs. 
Sham 
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Figure 7. Parasternal Long Axis View of Heart for Sham and HFpEF Mice. 
This figure shows the long axis view of the heart. You can clearly see the left 
atrium (LA) and LV and between them the mitral valve. This view is used to 
perform doppler echocardiography in order to measure diastolic parameters of 
the mice. The left image is taken from sham mice and right image is from HFpEF 
mice.  
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Figure 8. Parasternal Short Axis View of Left Ventricle for Sham and HFpEF 
Mice. This figure shows the short axis view through the LV for sham and HFpEF 
mice. The left image is taken from sham mice and right image taken from HFpEF 
mice. You can clearly see the hypertrophy of LV wall for the HFpEF mice which 
demonstrates our phenotype. This view is used to measure systolic parameters.  
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Figure 9. Mitral Doppler Echocardiography of Sham vs. HFpEF Mice. This 
figure shows the mitral Doppler echocardiography measurements of sham (top) 
and HFpEF (bottom) mice. Peak E indicates early transmitral flow velocity. Peak 
A indicates late transmitral flow velocity. DT indicates deceleration time and IVRT 
indicates isovolumetric relaxation time.  
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Figure 10. Dimensional LV Chamber Measurements of Sham vs. HFpEF 
Mice. This figure shows the LV dimensional measurements from short axis view 
of LV. HFpEF (bottom) mice demonstrates thicker IVS and LVPW as compared 
to sham (top) mice which is consistent with the LVEDD measurements showing a 
smaller chamber size for HFpEF mice compared to sham. 
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Figure 11. Basal Body Temperature, Acute Cold Tolerance Test, and Loss 
in Body Weight in Sham vs. HFpEF Mice. This figure demonstrates the data 
collected from acute tolerance test of sham and HFpEF mice. Basal body 
temperatures were comparable between the two groups. HFpEF demonstrates a 
more dramatic drop in body temperature throughout the cold tolerance test. 
Lastly, HFpEF mice shows a significant increase in lose of body weight after the 
CTT.  
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Figure 12. Weekly Blood Pressure and Pulse Measurements of Sham vs. 
HFpEF Mice. This figure shows the time course weekly blood pressure 
measurements for sham and HFpEF mice. We can see a significantly rise in SBP 
and DBP after week 2 for the HFpEF mice. HR were comparable throughout the 
4 weeks.  
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Figure 13. Glucose Tolerance Test and Weekly Body Weight Measurements 
for Sham vs. HFpEF Mice. This figure demonstrates the time course weekly 
body weight measurements and glucose tolerance test measurements. Body 
weights were consistently increasing in both sham and HFpEF mice. GTT results 
demonstrated similar level of glucose metabolism between sham and HFpEF 
mice.  
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Table 4. Echocardiographic Parameters of Sham, HFpEF, Shammac, 
HFpEFmac  mice after 4 weeks of Saline/Aldosterone infusion and 2 weeks of 
macitentan treatment.  
 
 Sham Shammac HFpEF HFpEFmac 
Relative Wall Thickness (mm) 0.48±0.02 0.46±0.03 0.69±0.05** 0.51±0.03## 
Total wall thickness (mm) 0.79±0.048 0.82±0.02 0.1±0.04** 0.88±0.02## 
Left Ventricle End Diastolic 
Dimension (mm) 
3.22±0.04 3.59±0.05 2.95±0.16 3.47±0.09## 
LV ejection fraction (%) 83.12±3.0 72.81±3.93 92.47±1.73 81.46±3.24 
E/A 1.46±0.1 1.57±0.14 1.85±0.16 1.63±0.14 
Deceleration time (ms) 18.88±2.88 18.06±2.73 16.95±3.13 19.48±1.82 
Isovolumetric relaxation time 
(ms) 
16.4±0.88 19.17±0.46 20.28±1.00* 20.42±1.93 
Data are expressed as mean ± SEM. *P<0.05 vs. Sham, **P<0.01 vs. Sham, 
***P<0.001 vs. Sham, #P<0.05 vs. HFpEF, ##P<0.01 vs. HFpEF, ###P<0.001 vs. 
HFpEF.  
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Table 5. General characteristics of Sham, HFpEF, Shammac, HFpEFmac  mice 
after 4 weeks of Saline/Aldosterone infusion and 2 weeks of macitentan 
treatment.  
 
 Sham Shammac HFpEF HFpEFmac 
Body weight (g) 25.27±0.91 25.83±0.49 25.18±0.67 25.29±0.39 
Spleen weight / Body 
weight (mg/g) 
3.34±0.18 3.38±0.27 4.02±0.19* 4.18±0.2 
Kidney weight / Body 
weight (mg/g) 
6.79±0.46 7.15±0.23 10.41±0.41*** 10.18±0.23 
Lung Wet/Dry Ratio 4.28±0.08 4.67±0.14 4.28±0.06 4.73±0.06 
Systolic blood pressure 
(mm Hg) 
122.9±7.43 121.9±7.47 133.3±7.03 131.6±5.84 
Diastolic blood pressure 
(mm Hg) 
80.6±5.51 81.73±9.02 100.3±7.86 105.4±4.80 
Heart rate (beats/min) 642.2±21.27 681.3±18.9 637±22.51 617.9±9.81 
Data are expressed as mean ± SEM. *P<0.05 vs. Sham, **P<0.01 vs. Sham, 
***P<0.001 vs. Sham, #P<0.05 vs. HFpEF, ##P<0.01 vs. HFpEF, ###P<0.001 vs. 
HFpEF. 
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DISCUSSION 
Obesity 
 Obesity is one of the leading risk factors associated with HFpEF (Lavie et 
al. 2013). The survival rate of patients exhibiting both HFpEF and obesity is 
abysmal. However, there exist a subgroup of obese patients that demonstrate a 
higher survival rate to HFpEF than even average patients. (Clark, Fonarow, and 
Horwich 2014). This phenomenon came to be termed the “Obesity Paradox”. 
Researchers have tried to explain the mechanisms behind the obesity paradox, 
some of which are listed in Table 1, but there are not any conclusive answers. 
Past research from Sam lab has demonstrated the beneficial effects of the 
adipokine adiponectin on HFpEF which demonstrates communication between 
the adipose tissue and the heart (Sam et al. 2010). Our goal is to explore the 
mechanism behind inter-tissue communication between adipose tissue and the 
heart through adipokines or cardiokines. Through this understanding, we can 
then further explore the benefits MHO can have on illnesses such as HFpEF. 
First, we wanted to explore the general characteristics of the adipose tissue in 
our HFpEF model. 
 In this study, aldosterone infusion mice developed hypertension, LV 
hypertrophy, and diastolic dysfunction which support our phenotype for HFpEF. 
Examining the three types of adipose tissues collected, we noticed significant 
changes. The epididymal and inguinal white adipose tissue both showed 
significant reduction in weight while the interscapular brown adipose tissue 
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showed gain in weight. Looking at the histological images, the adipocyte size for 
epididymal and inguinal adipose tissue were significantly smaller, and they are 
starting to resemble brown adipose tissue. The interscapular brown adipose 
tissue histological images were very similar between Sham and HFpEF mice. 
This drastic alteration in adipose tissue phenotype shows that the adipose tissue 
in the body is trying to compensate for HFpEF or is adversely affected by it. We 
performed a glucose tolerance test in order to verify if metabolism is affected in 
our HFpEF mice and they showed identical glucose metabolism capability as 
sham mice. Furthermore, we performed an acute cold tolerance test as it 
seemed the white adipose tissue is undergoing the browning process, which is 
for generating heat and regulating body temperature. Surprisingly, the HFpEF 
mice was not able to endure the cold tolerance test as their body temperature 
dropped below 25 degree Celsius and we had to remove them from the cold 
room. This study shows that in our HFpEF model, inter-tissue communication is 
definitely occurring between adipose tissue and the heart. The adipose tissues in 
our HFpEF mice were displaying a very difference phenotype and more 
molecular studies can tell us their exact differences in gene and protein 
expression. We have to further explore what that communication encompasses 
in order to understand the role adipose tissue plays in HFpEF.   
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Hypertension 
The use of ERA has shown very promising results in PAH, especially the 
recently approved macitentan (Temple et al. 2014). ET-1 levels are elevated in 
HF patients which leads to elevated aldosterone levels. Previous clinical trials 
such as the TOPCAT trial using anti-aldosterone treatment proved to be 
ineffectual as the primary end point was not reached (Pitt et al. 2014). As the 
dual ERA bosentan decreased aldosterone levels in patients with congestive 
HFrEF, we hypothesized that dual ERA macitentan could potentially attenuate LV 
hypertrophy, improved diastolic dysfunction, and reverse adverse cardiac 
remodeling in HFpEF model.  
In this study, sham and HFpEF mice were put on 2 weeks of macitentan 
chow after 2 weeks of chronic aldosterone or saline infusion. HFpEF mice 
without macitentan developed hypertension, LV hypertrophy, and diastolic 
dysfunction. Based on hemodynamic data, macitentan was not able to lower 
systolic BP in sham or mice with HFpEF after the development of hypertension. 
Diastolic dysfunction, as measured by an increased E/A ratio, was also not 
affected by macitentan. However, macitentan significantly modulated total wall 
thickness (TWT) and relative wall thickness (RWT) after 2 weeks of therapy. It is 
thus plausible that macitentan may improve HFpEF by improving adverse cardiac 
remodeling and hypertrophy.  
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Conclusion 
 In conclusion, our exploration into the adipose tissue of our HFpEF model 
demonstrated very interested results. The adipose tissue is displaying a 
completely different phenotype as compared to the sham mice, which shows that 
some sort of communication is definitely occurring between the adipose tissue 
and the heart. As to what that communication is, and through which mechanism it 
is happening, further research is required. With more molecular data on the 
collected adipose tissue, we can explore differences in gene and protein 
expression in the adipose tissue. Furthermore, we can use a murine model of 
metabolically healthy obesity to further investigate the benefits of healthy obesity 
on HFpEF.  
 Our study on the use of ERA macitentan in attenuating HFpEF parameters 
proved to have mixed results. Macitentan was not able to reduce hypertension or 
diastolic dysfunction parameters. However, macitentan proved to be effective in 
reducing cardiac hypertrophy. It is then possible that macitentan can improve 
HFpEF by reducing cardiac remodeling and hypertrophy.  
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